- Published on
Clinical Toxicology — Scorpion Envenomation
1. Overview
Scorpion envenomation occurs when a scorpion injects venom through the stinger located at the end of its tail.
Most scorpion stings cause localized pain and paresthesia without significant systemic toxicity. However, certain species can produce life-threatening neurologic, autonomic, respiratory, or cardiovascular complications.
Clinical severity depends on the scorpion species, quantity of venom delivered, patient age, underlying health, and time to treatment.
Two major patterns of severe envenomation must be distinguished:
- Predominantly neurotoxic envenomation, particularly associated with the Arizona bark scorpion, Centruroides sculpturatus.
- Autonomic and cardiopulmonary toxicity, particularly associated with several medically important species in Asia, Africa, and Latin America.
Young children are at increased risk of severe effects, although adults can also develop life-threatening toxicity.
The principal treatments are supportive care, early recognition of respiratory or cardiovascular compromise, and species-appropriate antivenom when indicated and available.
2. Medically important scorpion species
North America
The Arizona bark scorpion, Centruroides sculpturatus, is the principal native U.S. scorpion associated with potentially life-threatening neurotoxicity.
It occurs primarily in Arizona and adjoining regions of the southwestern United States and northwestern Mexico.
The historical name Centruroides exilicauda was previously applied to this scorpion, but current taxonomy recognizes C. sculpturatus as a distinct species.
Other native U.S. scorpions usually cause localized pain and limited systemic effects.
Mexico and Central America
Several Centruroides species can cause clinically important envenomation.
The risk varies substantially by region and species.
South America
Certain Tityus species are medically important, particularly in Brazil.
Severe envenomation may involve vomiting, autonomic instability, myocardial dysfunction, pulmonary edema, and shock.
South Asia
The Indian red scorpion, Mesobuthus tamulus, can produce severe cardiovascular toxicity and pulmonary edema.
North Africa and the Middle East
Medically important genera include Androctonus, Leiurus, and Buthus.
Depending on the species, severe envenomation may produce neurologic excitation, autonomic dysfunction, and cardiopulmonary complications.
Clinical implication
Treatment protocols developed for Arizona bark scorpions cannot automatically be applied to scorpion envenomation elsewhere in the world.
The local species and available antivenom are essential considerations.
3. Mechanism of toxicity
Scorpion venom contains mixtures of biologically active substances, including peptides that affect ion channels.
Many medically important toxins alter the activity of neuronal voltage-gated sodium channels.
Some toxins also affect potassium, calcium, and other ion channels.
Neuronal excitation
Changes in ion-channel function interfere with normal electrical signaling and can cause repetitive neuronal firing.
This produces neuromuscular hyperactivity and abnormal autonomic responses.
Autonomic activation
Severe envenomation can increase sympathetic and parasympathetic activity.
Clinical findings may include tachycardia, hypertension, sweating, excessive salivation, vomiting, and other autonomic manifestations.
Cardiovascular injury
In certain species, intense catecholamine release and other venom effects can cause myocardial dysfunction, impaired ventricular contraction, pulmonary edema, and shock.
The mechanisms are complex and are not identical across scorpion species.
4. Toxic dose and risk factors
A clinically useful toxic dose cannot be defined by the number of stings alone.
A single sting can cause severe systemic envenomation in a susceptible patient.
Risk factors
Important factors include young age, small body size, significant underlying cardiac or respiratory disease, and delayed access to appropriate treatment.
Stings occurring in regions with highly venomous species require particular caution.
Children
Young children may deteriorate rapidly.
They can develop severe neuromuscular hyperactivity, impaired swallowing, excessive secretions, and respiratory compromise.
Older adults
Older patients may tolerate severe tachycardia, hypertension, or myocardial stress poorly.
Important distinction
A relatively normal-looking sting site does not exclude severe systemic envenomation.
5. Clinical manifestations
Local findings
The most common initial symptom is immediate pain at the sting site.
Patients may describe burning, electric-shock-like pain, tingling, numbness, or hypersensitivity.
Visible swelling and redness may be minimal or absent.
Some patients experience marked pain when the affected area is touched or tapped.
Neurologic manifestations
Severe Centruroides envenomation may produce:
- Agitation and restlessness.
- Involuntary or poorly coordinated limb movements.
- Muscle fasciculations.
- Abnormal eye movements.
- Difficulty controlling the tongue and facial muscles.
- Slurred speech.
- Difficulty swallowing.
Roving eye movements
Children may develop repetitive, disconjugate, or rotary eye movements.
These findings are characteristic of significant Centruroides neurotoxicity.
Neuromuscular hyperactivity
Patients may exhibit uncontrolled movements, posturing, or marked muscle activation.
These movements can resemble epileptic seizures.
However, many affected children remain conscious despite dramatic motor activity.
True seizures are less characteristic and should prompt consideration of alternative or additional diagnoses.
Autonomic findings
Possible manifestations include tachycardia, hypertension, sweating, hypersalivation, vomiting, and pupillary changes.
Respiratory complications
Patients may develop difficulty swallowing, inability to manage secretions, choking, stridor, hypoxemia, or respiratory failure.
In severe non-U.S. envenomation, cardiogenic pulmonary edema may be particularly important.
Cardiovascular complications
Depending on species, findings may include persistent tachycardia, hypertension, myocardial dysfunction, hypotension, and shock.
6. Clinical severity
A practical approach separates envenomation into three broad categories.
Mild envenomation
Pain or paresthesia is confined to the sting site.
There is no clinically significant neuromuscular, autonomic, respiratory, or cardiovascular dysfunction.
Moderate envenomation
Pain or paresthesia may extend beyond the sting site.
Mild abnormal movements or autonomic manifestations may be present, but airway protection and circulation remain stable.
Severe envenomation
Features include important cranial nerve dysfunction, uncontrolled skeletal muscle activity, severe hypersalivation, respiratory distress, pulmonary edema, shock, or other organ dysfunction.
Formal grading systems vary by geography and clinical protocol.
Antivenom decisions should reflect clinically important systemic effects, not pain severity alone.
7. Diagnosis
Diagnosis is generally clinical.
Exposure history
Establish the time and location of the sting, observed scorpion characteristics, onset of symptoms, and clinical progression.
Photographs may help with identification when obtained safely.
Patients should not attempt to capture a live scorpion if doing so creates additional risk.
Examination
Assess vital signs, pain, neurologic function, swallowing, secretions, oxygenation, and cardiovascular status.
In children, observe for abnormal eye movements, uncontrolled limb activity, excessive salivation, and difficulty maintaining the airway.
Laboratory investigations
Routine testing is usually unnecessary in uncomplicated localized envenomation.
Patients with significant systemic toxicity may require glucose, electrolytes, kidney function, blood gas, and other investigations according to the presentation.
Cardiac assessment
In areas where cardiotoxic species occur, ECG, cardiac biomarkers, chest imaging, and echocardiography may be appropriate for patients with significant cardiovascular or respiratory findings.
Muscle injury
Creatine kinase and kidney function may be useful after prolonged severe muscle activity.
Seizure evaluation
EEG is reserved for patients in whom true seizures or nonconvulsive status epilepticus are suspected.
8. Differential diagnosis
Localized sting pain may resemble injury from ants, bees, wasps, spiders, or other arthropods.
Severe neurotoxic envenomation can resemble exposure to sympathomimetic drugs, anticholinergic agents, or certain neurotoxic pesticides.
In young children, agitation and abnormal movements can also resemble febrile seizures, epilepsy, or central nervous system infection.
The diagnosis should be reassessed when the clinical syndrome is inconsistent with the scorpion species likely to be present locally.
9. Initial management
Immediate priorities
Remove the patient from further exposure.
Assess airway, breathing, circulation, consciousness, and the ability to swallow or control oral secretions.
Children with systemic neurologic symptoms require urgent emergency assessment.
First aid
Wash the sting site gently with soap and water.
A cool compress may help relieve localized pain.
Rest the affected limb when appropriate.
Avoid applying ice directly for prolonged periods.
Treatments to avoid
Do not cut the wound, attempt suction, apply electrical shocks, or use a tourniquet.
These measures do not reliably remove venom and may cause additional harm.
Tetanus
Review tetanus immunization status and provide prophylaxis when indicated according to standard wound-management guidance.
Pain control
Acetaminophen or ibuprofen may be appropriate for mild localized pain when no contraindication exists.
More significant pain may require clinician-administered analgesia.
Local anesthetic techniques can be considered in selected cases.
10. Management of severe systemic envenomation
Airway protection
Loss of pharyngeal muscle control, excessive secretions, and uncontrolled movements may threaten airway patency.
Patients with severe symptoms need continuous respiratory assessment.
Suction, oxygen, and advanced airway equipment should be immediately available.
Endotracheal intubation may be necessary for respiratory failure or inability to protect the airway.
Benzodiazepines
Benzodiazepines can help control severe agitation and neuromuscular hyperactivity.
However, repeated or high doses may worsen respiratory depression and impair airway protection.
Sedation is supportive treatment; it does not neutralize venom.
Where appropriate antivenom is available, its use should not be delayed merely to escalate sedative doses in a patient with severe envenomation.
Pulmonary edema and shock
Patients with cardiopulmonary toxicity require careful hemodynamic assessment.
Treatment may include oxygen, ventilatory support, and specialist-directed vasoactive medications.
Excessive fluid administration may worsen pulmonary edema when myocardial dysfunction is present.
Management should follow the clinical syndrome and local species-specific protocols.
11. Antivenom in the United States
Anascorp
Anascorp is the FDA-approved antivenom for clinically important Centruroides scorpion envenomation.
Its generic description is Centruroides (scorpion) immune F(ab′)₂ (equine).
The product consists of purified antibody fragments derived from horses immunized with venom from selected Centruroides species.
It was approved by the FDA in 2011.
Indications
The prescribing information recommends prompt treatment for clinically important manifestations such as:
- Loss of muscle control.
- Roving or abnormal eye movements.
- Slurred speech.
- Respiratory distress.
- Excessive salivation or frothing.
- Other significant systemic symptoms.
Minor localized pain alone does not generally require antivenom.
Initial dose
The FDA-approved initial dose is:
Three vials intravenously over 10 minutes.
Each vial is reconstituted with 5 mL of normal saline.
The three reconstituted vials are combined and diluted to a total volume of 50 mL of normal saline.
Additional doses
If clinically important symptoms persist, one additional vial may be administered at 30–60-minute intervals, with reassessment after each infusion.
The antivenom should be administered by appropriately trained clinicians following current product instructions and poison-center guidance.
Adult and pediatric treatment
The initial labeled dose is the same for adults and children.
This reflects treatment of the injected venom rather than simple body-weight-based dosing.
Clinical response
Patients with severe Centruroides envenomation often improve rapidly after appropriate antivenom treatment.
Clinical trials demonstrate substantially faster resolution of neuromuscular toxicity compared with supportive care alone.
12. Antivenom safety
Acute hypersensitivity
Anascorp can cause allergic reactions, including potentially life-threatening anaphylaxis.
The prescribing information emphasizes particular caution in patients with previous reactions to equine proteins or equine-derived antivenoms.
A history of horse-protein allergy increases risk but is not listed as an absolute contraindication to Anascorp.
Skin testing
The historical requirement for intradermal antivenom skin testing should be removed.
Routine pretreatment skin testing is not required by the current FDA-approved Anascorp label and cannot reliably exclude a serious reaction.
Emergency preparedness
Antivenom should be administered in a setting equipped to recognize and treat anaphylaxis.
If anaphylaxis develops, stop the infusion and provide immediate appropriate emergency treatment.
Serum sickness
Delayed hypersensitivity reactions may occur after treatment.
Symptoms include fever, rash, itching, joint pain, and malaise.
The FDA prescribing information reports symptoms suggestive of serum sickness in approximately 0.5% of patients enrolled in clinical studies.
This differs substantially from the high historical serum-sickness rates associated with older antivenom preparations.
Follow-up
Patients should be instructed to seek assessment for delayed allergic symptoms during the first 14 days after treatment.
13. Evidence supporting antivenom
A randomized, double-blind, placebo-controlled trial published in the New England Journal of Medicine in 2009 examined F(ab′)₂ antivenom for children with severe Centruroides envenomation.
All eight children receiving antivenom had resolution of the clinical syndrome within four hours, compared with one of seven receiving placebo.
Patients receiving antivenom also required less midazolam.
Although the randomized trial was small, subsequent clinical studies support the conclusion that antivenom can rapidly reverse severe neurotoxic symptoms.
Clinical implication
Antivenom is an effective specific treatment for severe Centruroides neurotoxicity and should not be regarded as merely experimental or reserved only for failure of prolonged sedation.
14. Severe scorpion envenomation outside North America
The management of serious scorpion envenomation elsewhere requires local expertise.
Indian red scorpion
Mesobuthus tamulus can produce an intense autonomic response followed by myocardial dysfunction and pulmonary edema.
Prazosin
Prazosin, an alpha-1 adrenergic antagonist, is used in India for systemic cardiovascular manifestations of Indian red scorpion envenomation.
Evidence supports its usefulness, particularly when treatment is initiated early.
Antivenom and prazosin
Controlled studies indicate that combining species-appropriate antivenom with prazosin can improve outcomes or accelerate symptom resolution compared with prazosin alone in certain Indian red scorpion envenomations.
Cardiovascular support
Patients with myocardial dysfunction may require intensive-care treatment and specialist-directed vasoactive medications.
Dobutamine has been used in selected patients with impaired ventricular contraction.
Geographic limitation
Prazosin is not a universal antidote for scorpion stings.
Its role in Mesobuthus tamulus envenomation should not be extrapolated automatically to Arizona bark scorpion poisoning.
Likewise, Anascorp should not be assumed to neutralize all medically important scorpion venoms worldwide.
Other regional antivenoms
Antivenoms used in Mexico, North Africa, South America, and other regions vary in composition, potency, clinical evidence, and species coverage.
Treatment should follow local clinical protocols and antivenom availability.
15. Pregnancy and breastfeeding
Pregnancy
Clinical evidence remains limited.
A pregnant patient with significant scorpion envenomation requires prompt assessment of maternal respiratory and cardiovascular function.
Maternal hypoxemia, shock, or severe systemic illness may also endanger the fetus.
Appropriate antivenom should not be withheld solely because of pregnancy when the expected benefits outweigh the risks.
Obstetric assessment and fetal monitoring should be considered according to gestational age and severity.
Breastfeeding
Evidence regarding antivenom transfer into breast milk is limited.
Equine-derived F(ab′)₂ fragments are large protein molecules, and clinically important infant exposure through breast milk is not expected to be substantial.
Nevertheless, management should be individualized, particularly when the infant is premature or medically vulnerable.
16. Observation and disposition
Mild localized envenomation
A patient with localized pain, normal vital signs, and no systemic symptoms may be suitable for outpatient management after appropriate assessment.
A period of observation is particularly useful in young children or after suspected Centruroides exposure.
Young children
Because severe symptoms may develop rapidly, a low threshold for emergency evaluation is appropriate.
Significant neurologic symptoms
Patients with abnormal eye movements, excessive secretions, uncontrolled movements, difficulty swallowing, or respiratory symptoms require monitored care.
After antivenom
The patient should be monitored closely during infusion and for at least the subsequent period specified in the prescribing information.
Additional observation depends on clinical response, recurrence of symptoms, and complications.
A fixed four- to six-hour observation period should not replace individualized assessment.
Hospital admission
Admission is appropriate for persistent neurologic toxicity, significant respiratory symptoms, uncontrolled pain requiring hospital therapy, or cardiovascular complications.
Intensive care
ICU treatment is indicated for respiratory failure, inability to protect the airway, severe pulmonary edema, shock, or other critical organ dysfunction.
Discharge
Discharge is appropriate when vital signs are stable, systemic symptoms have resolved or are clearly improving, the patient can swallow and manage secretions normally, and further emergency treatment is unlikely to be necessary.
Patients treated with antivenom need counseling regarding delayed hypersensitivity.
17. Expected course and prognosis
Mild envenomation
Localized pain and paresthesia generally improve over hours and may persist into the following day.
Severe
Centruroides
envenomation
Without antivenom, significant neurologic symptoms may persist for many hours and occasionally longer.
With appropriate antivenom treatment, resolution is commonly much faster.
Cardiovascular envenomation
Some medically important species can cause prolonged myocardial dysfunction, pulmonary edema, and shock.
Recovery depends on the severity of organ injury and the speed of effective treatment.
Mortality
Death is uncommon after U.S. scorpion stings when appropriate medical care is available.
However, severe systemic envenomation remains an important cause of illness and death in certain regions worldwide, particularly among children.
18. Prevention
Scorpions commonly shelter beneath rocks, wood, debris, and other protected surfaces.
Some species enter homes and hide in shoes, clothing, bedding, or stored materials.
Recommended precautions include:
- Inspecting shoes, clothing, sleeping bags, and bedding.
- Wearing protective footwear in endemic areas.
- Using gloves when handling wood, rocks, or outdoor debris.
- Reducing clutter around buildings.
- Sealing openings through which scorpions may enter.
- Avoiding direct handling of scorpions.
In areas with frequent household exposure, appropriate pest-management measures can reduce risk.
19. Clinical pitfalls
Using the outdated species name as the only identifier. The Arizona bark scorpion is now recognized as Centruroides sculpturatus.
Assuming all scorpions cause the same syndrome. Neurologic and cardiopulmonary manifestations differ substantially by species and geography.
Assuming a normal sting site excludes serious toxicity. Severe bark scorpion envenomation can occur with minimal local findings.
Mistaking neuromuscular hyperactivity for seizures. Dramatic involuntary movements may occur while the child remains conscious.
Overlooking swallowing and secretion control. These are critical indicators of airway risk.
Using excessive sedation instead of evaluating for antivenom. Benzodiazepines do not neutralize venom and may impair breathing.
Describing Anascorp as an unapproved goat-derived product. It is an FDA-approved equine F(ab′)₂ antivenom.
Using the historical one- to two-vial initial dose. Current Anascorp labeling specifies three vials initially.
Performing routine antivenom skin testing. It is not required and does not reliably predict anaphylaxis.
Assuming horse allergy always prohibits antivenom. The current product has no listed absolute contraindications, though hypersensitivity precautions are essential.
Assuming the older serum-sickness rates apply to Anascorp. The FDA trials reported a substantially lower rate.
Applying prazosin to all severe scorpion stings. Its evidence is primarily relevant to particular cardiotoxic species, especially the Indian red scorpion.
Neglecting cardiopulmonary assessment in severe non-U.S. envenomation. Myocardial dysfunction and pulmonary edema may dominate.
Using a universal observation or discharge interval. Clinical severity and recovery should guide disposition.
Key clinical conclusions
Scorpion envenomation ranges from localized pain to life-threatening neurologic and cardiovascular toxicity.
In the southwestern United States, the Arizona bark scorpion can produce severe neuromuscular excitation, abnormal eye movements, excessive secretions, and respiratory compromise.
Anascorp is an effective FDA-approved antivenom for clinically important Centruroides envenomation. Its labeled initial dose is three vials intravenously over 10 minutes, followed by additional single-vial doses when required.
In other regions, especially parts of South Asia, Africa, and Latin America, severe scorpion envenomation may predominantly affect the heart and lungs. Management may involve species-specific antivenom, prazosin in selected settings, and intensive cardiovascular support.
Prompt recognition, airway assessment, appropriate antivenom use, and careful monitoring are central to preventing serious complications.